Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
Phase 3
Completed
- Conditions
- Hyperlipidemia
- Registration Number
- NCT00137462
- Lead Sponsor
- Pfizer
- Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
- Detailed Description
For additional information please call: 1-800-718-1021
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 900
Inclusion Criteria
- Statin eligible per NCEP ATP-III guidelines
- At least 18 years of age
Exclusion Criteria
- Women who are pregnant or lactating, or planning to become pregnant
- Intolerance to statin therapy
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in lipid parameters (HDL, LDL) at various timepoints over 12 months.
- Secondary Outcome Measures
Name Time Method Changes in levels of lipids and other biomarkers.
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇨🇦St. Georges de Beauce, Quebec, Canada